this Thank you for you, afternoon. all Pete joining and us thank
mission day. set the priorities an as because Our longer the with our decisions medicines cancer our it's every at lives. begin behind promise live the the force we've I'd is mission statement to to we Kura with organization realize calls better, precision driving of help patients and like make to
serves families the reminder as we patients do and to current it what in their and we important why commitment Our environment. is an do
timing are conduct stage see drug to COVID-XX from our trials. As with and clinical pandemic effects beginning on clinical companies, the development we the of other
Furthermore, on ability for which our our new Specifically, screening to an enrollment. impact sites related and are candidates and having fewer impact trials. on may our initiate sites who is both ongoing social trials, percussions the pandemic having new an are seeing be patients, and patient clinical open
mitigation incorporating these very financial operating with expect steps. health the goal of recently to potential continue response against a to challenges of still stakeholder that with pandemic the pandemic a those value providers we the although completed the number patients, for uncertainty the multiple we position. as And the In review, the programs strategic and and disruption In prioritizing feedback create and context, while shareholders, continues. to of situation the challenges, a for care strong maintaining is COVID-XX we've future foreseeable COVID-XX implemented fluid, highest
key Our review resulted in strategic outcomes. three
activities First, including Transferase neck dependent mutant cell we related and carcinomas inhibitors, HRAS HRAS Tipifarnib intend expand to overexpressed HNSCC. squamous Farnesyl HRAS to and head our in
menin of serve leukemias and We major one our our now KO-XXX two leukemias. and of have also will inhibitor prioritized acute and acute KO-XXX NPMX-mutant alongside pillars Tipifarnib and KMTXA(MLL)-rearranged HNSCC. development as HRAS-mutant
to and related we optimize activities T-cell to CXCLXX-driven while opportunities development. Tipifarnib Second, in including pause to time pancreatic plan cancer, these future taking for tumors, lymphoma
KO-XXX. ERK to development decided we've Third, our inhibitor terminate of
enhance to Tipifarnib believe AML. value potential While adult through clinical value programs points' the potential from development position those with these clinical strong inflection to focusing a us data namely highest decisions, HNSCC in those us enables enables focus our were our we maintain difficult on KO-XXX and from cash efforts development and and
ASCO, abstracts HRAS-mutant very ongoing have of Phase HNSCC. oral that from presentation that accepted an outcome data pleased presentation, in featuring report I'm three II including Tipifarnib matured at been to for the study clinical we have
we HRAS benefit later at to population month. ASCO in response the mutant high patients a data with meaningful and to look frequency, allele variant high addition to rate see a in HRAS-mutant we sharing encouraged this overall forward In are those clinical
trial set, HRAS-mutant being treated. to we on variant are HRAS-mutant part Phase HNSCC who regardless in allele patients frequency, AIM-HN patients, data of the registration-directed II enroll HNSCC expanding to all proportion our Based the intend of amend
maintain goal potential overall is benefit of variant population. also rate measure mutant will HRAS to assess primary high our Although, the we clinical objective the outcome mutant in response in the frequency, with HNSCC allele patients HRAS
In addition treat this desire indicated mature from in from HRAS II the HNSCC feedback more all to to response the motivated trial, are physicians to data who've we Phase received make sets patients. mutant the change we've to
low potential patients. survival heard we'll present current to Based with treatment on options benefit. rates these the ASCO, teens benefit have in meaningful a from that at provide we Tipifarnib moderate to has physicians limited, the the We response are data and believe
quickly We intend throughout amendment continue existing and to we'll sites implement clinical this patients our process. the as to as at possible enroll
more communicate AIM-HN the trial to data ASCO. presentation following the to the on specifics expect We amendment at
trial remains a of AIM-HN Tipifarnib HRAS mutant primary need, of Our disease unmet focus. in HNSCC, a high
amendment guidance on the the we for on proposed ongoing impact screening suspending are clarity our and more have until enrollment timing. However, full on given we the trial, and of COVID-XX enrollment
expand and In first addition registrational therapy. how mutant of recurrent of planning earlier metastatic HNSCC, in lines we to or use for Tipifarnib HRAS the can also larger into opportunity we're the pursuing patient populations
XX% of we preclinical HRAS, the in with patient. clinical in increasingly other distinct biology Tipifarnib be can treat intend to overexpress HNSCC have upon These HRAS may need interested targeted the It's of as dependent estimated drive encouraging our the tumors pursue therapies unmet are resistance gene. overexpressing HNSCC to a particular, to other combination Tipifarnib. development patients HNSCC that may to data, Based a and patients we up strategy which HRAS therapies. patients overexpressed represent In of significant that tumors, that tumors whose HRAS by subset with
to turn quickly let's in our CXCLXX-driven Now, Tipifarnib tumors. attention
CXCLXX the indications. of biomarkers that therapeutic the to value inhibitors Farnesyl tumor have across believe unlock to of Transferase continue hematologic pathway potential We solid range and a
month, the last of its for received a the from need orphan Just lymphoma, Tipifarnib address recognizing potential for designation unmet T-cell treatment FDA drug to high patients.
pandemic. we call, especially in believe the earlier new the outlined global I initiation during reasons studies are a of for However, challenging
initiation cancer. use board to T-cell registration-directed Tipifarnib study proposed for are this of in and opportunities meetings, proof-of-concept time our trial refine we to as intend pausing these treatment of lymphoma, market additional our development. as future conduct advisory We well So optimize of insights further our second-line in the pancreatic
That KO-XXX and interaction. focus support data area genetically subsets need. also and as antitumor this to of is received a population mutation. as brings rearrangements acute to inhibitor address KO-XXX the drug of myeloid its KMTXA(MLL) major unmet fusions Preclinical patients with protein-protein such for us orphan small the potential has potential FDA well of KO-XXX. potent the for from designation potent defined leukemia, recognizing KMTXA(MLL) our molecule as selective NPMX treatment activity high in second of menin the
that chemically We inhibitor excitement were in Gerard the a can activity AACR last underscore which AML meaningful antitumor properties. KO-XXX, McGeehan chemical pleased This week, drive and to see the our around presentation is represented with public patients. encouraging only physical from different report which distinct first KMTXA(MLL)-rearranged Dr. data molecule menin at drug-like
in We clinical dosed AML trial the relapsed/refractory And our patient in of late named in the year. Phase KO-XXX X/Xa dose which last trial KOMET-XXX have escalation. first continues we
progress by we're the it's we're clinic. Although, in early, making the encouraged still
the after our on which we NPMX KMTXA(MLL) which reaching remain rearranged We activity safely enable increased We potential where goal Phase Selected cohorts at antitumor dose. us clinical mutant of in recently benefit. drive aggressively can to into following move we the populations focused cohorts open a a demonstrate AML. protocol X believe to and expansion expansion KO-XXX patient has we dose amended intend to the to recommended achievement of
major the the opportunity options well with In label, in XX% expand as the to all potentially about therapies. believe children the the and AML in both such, with its that as patients. differentiated broadening development We're And KO-XXX exploring as represents addition, AML, have a approximately one HRAS-mutant KO-XXX prioritized further our approach HNSCC. treatment and of to of of of we combination target alongside to pillars, treatment acute the and potential. chemotherapy patients leukemias targeted Tipifarnib its as are with potential of two We adults, enthusiastic
placed drug hold, a candidate study. on small I reaction, remaining selective of to trial this Earlier clinical in was partial patient a year KO-XXX, adverse our due drug dose-limiting, single on molecule is of Phase a inhibitor a Our KO-XXX ERK.
solid interest and I'd their amplified to opted to in lifted, development KO-XXX. like thank Although the our their further has we've of the to all patients XXqXX families and opportunity terminate this been partial participation especially clinical take hold remains, tumors and of in for study. investigators the the
and and two who portfolio, prioritizing advancing commitment KO-XXX After our resources demonstrates a our critically of treat strategic we therapies, higher HNSCC shareholders. our value. interest patients benefit patients new to patients This the decision our who health in of that care providers our believe and create programs need focus we've these thorough to have decided review AML, Tipifarnib instead potential to in toward a
discussion the of that, Grasso over With for to Marc turn our a results, financial first the I'll call now quarter for XXXX.
